Products for Research Use Only

Vemurafenib (Standard)

CAT: 0804-HY-12057R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12057R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vemurafenib (Standard) is the analytical standard of Vemurafenib. This product is intended for research and analytical applications. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].
CAS Number
918504-65-1
Product Name Alternative
PLX4032 (Standard) ; RG7204 (Standard) ; RO5185426 (Standard)
UNSPSC
12352005
Target
Autophagy; Raf; Reference Standards
Type
Reference Standards
Related Pathways
Autophagy; MAPK/ERK Pathway; Others
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vemurafenib-standard.html
Smiles
FC1=CC=C(C(F)=C1C(C2=CNC3=NC=C(C=C32)C4=CC=C(C=C4)Cl)=O)NS(CCC)(=O)=O
Molecular Formula
C23H18ClF2N3O3S
Molecular Weight
489.92
References & Citations
[1]Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467 (7315), 596-599.|[2]Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010, 70 (13), 5518-5527.|[3]Prahallad A, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483 (7387), 100-103.|[4]Shelledy L, et al. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or MetastaticMelanoma. J Adv Pract Oncol. 2015 Jul-Aug;6 (4) :361-5.|[5]Wang W, et al. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.J Clin Endocrinol Metab. 2017 Feb 1;102 (2) :634-643.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards